Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | -2.15% | 152.86 | 0.7% | $1193.05m | |
| PFE | Pfizer Inc. | -0.16% | 34.34 | 0.9% | $1183.43m | |
| MRK | Merck & Co., Inc. | -1.56% | 72.16 | 0.7% | $851.01m | |
| BMY | Bristol-Myers Squibb Co. | -2.03% | 59.52 | 1.0% | $795.69m | |
| ABBV | AbbVie, Inc. | -0.78% | 105.88 | 1.9% | $740.30m | |
| LLY | Eli Lilly & Co. | -0.78% | 200.42 | 1.1% | $642.23m | |
| AZN | AstraZeneca Plc | -0.46% | 46.95 | 1.2% | $494.96m | |
| GSK | GlaxoSmithKline Plc | -0.35% | 34.12 | 0.2% | $282.66m | |
| NVS | Novartis AG | -1.02% | 83.32 | 0.2% | $165.42m | |
| SNY | Sanofi | 0.37% | 45.63 | 0.2% | $156.73m | |
| VTRS | Viatris, Inc. | -3.06% | 13.46 | 0.0% | $147.23m | |
| VERU | Veru, Inc. | -8.44% | 12.04 | 0.0% | $100.15m | |
| NVO | Novo Nordisk A/S | -2.98% | 69.33 | 0.1% | $84.61m | |
| KALV | KalVista Pharmaceuticals, Inc. | -3.60% | 31.03 | 0.4% | $80.73m | |
| RPRX | Royalty Pharma Plc | -3.70% | 41.96 | 0.2% | $79.81m |
Company Profile
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.